Why is it so important to have greater representation of minority groups in clinical trials? “If we don’t have proper representation of all races, all cultures, everyone, then we’re not getting results for everyone that will be taking it.” Tiffany Ashton. In our latest clinical diversity webinar, Race in STEM community director Steven Fuller and a panel of Tiffany Ashton, MAS, CCRA, Barry Holmes Jr., Téa Romero, MPsy, MBA and Michael W. Young discussed the importance of representation in clinical trials and how we can understand and overcome the barriers to ensure more diverse participation. Watch the webinar here: https://lnkd.in/e5NqFHCt #webinar #insight #diversityequityinclusion #dei #biotech #pharma #stem #recruitment
Race in STEM’s Post
More Relevant Posts
-
What does #diversity in #clinicaltrials really mean? The FDA's new Diversity Action Plan Guidance emphasizes what we've paid a lot more attention to in recent years, such as race, ethnicity, age of participants, and sex of participants, but also pays close attention to geographical location, socioeconomic status, disabilities, and more. In this Applied Clinical Trials Magazine video interview, Curavit's CMO and Co-Founder, Pam D., says she hopes "that these guidelines will lead to greater trust across the industry, whether it's increased trust between sponsors and regulatory organizations, but more importantly, in [her] mind, hoping it will increase trust between sponsors, CROs, and potential trial participants." #DTx #DCTs #digitalhealth #pharma #biotech #clinicalresearch Hear more from Pam and other industry experts on the new plan guidance here: https://lnkd.in/g6WXYdpj
Industry Leaders React to FDA's Newly Announced Diversity Action Plan Guidance
appliedclinicaltrialsonline.com
To view or add a comment, sign in
-
I had the pleasure of speaking with Behtash Bahador, of CISCRP earlier this week, and very excited to see that the 2023 Perceptions and Insights study has been published. Conducted every 2 years, this study helps establish a routine global assessment of trends in perceptions and clinical research experiences. Some of my personal highlights: General understanding of 'clinical trials' and 'clinical research' saw an increase from 85% (2022), to 91% (2024) Willingness to participate in clinical research also saw an increase from 77% (2021), to 91% (2023) Online channels continue to grow as the number 1 (36%) source of information when researching clinical trials to participate in, with patient advocacy groups a close 2nd (30%) #clinicaltrials #clinicalstudies #clinicalresearch #patientexperience
Perceptions and Insights Study
https://www.ciscrp.org
To view or add a comment, sign in
-
Please join me via live webinar for the The National Academies’ Forum on Drug Discovery, Development, and Translation and Roundtable on Black Men and Black Women in Science, Engineering, and Medicine workshop October 16-17, 2023. This webinar will consider what is needed to support the next generation workforce in drug research and development (R&D)– one that is resilient, culturally aware, anti-racist, and interdisciplinary. This webinar builds upon the Forum on Drug Discovery, Development, and Translation’s 2021 workshop series, “Envisioning a Transformed Clinical Trials Enterprise for 2030. #DrugForum #ClinicalTrials #Workforce #DiversityInSTEM
Preparing the Future Workforce in Drug Research & Development - A Workshop | National Academies
nationalacademies.org
To view or add a comment, sign in
-
Chief Marketer // Former Chief Executive // Intel, Verizon, IPG, Publicis alum // DE&I Human Rights Board Member // Shared Creative Joy
Yesterday, my company posted about our perspective on a huge topic in clinical research: diversity. The post started a lot of great discussion. The topic leads to a fundamental question: "Do we believe that new medicines should work for everyone?" As in many other industries, there has been a lot of talk about diversity but not a lot of evidence that real headway is being made. Data, tech and AI will all help to some degrees. But to make a real impact, to achieve more than just intent, we need to take a more human approach that makes clinical research work for each community, not the other way around. Whether you work in clinical research or not, I encourage you to read our post. Comment on it. Like if you agree. Thanks for your time.
What is a diverse research site? It’s not just about diversity of staff and participants – but also diversity in how clinical research is woven into the fabric of local communities. This highlights how crucial adaptability is for sponsors, CROs, and sites to find the most appropriate and effective ways of working. Not all sponsors and protocols allow for this flexibility, but we are getting there. Take these new studies at Care Access sites for example: - Novo Nordisk checking fatty livers in a quaint rural clinic https://bit.ly/46xBpID - Eli Lilly and Company screening Lp(a) next door to a Historically Black College and University (HBCU) community center https://bit.ly/3PKp4Kt - Anthos Therapeutics detecting heart palpitations inside of a safety-net community hospital https://bit.ly/3LNFNvb - Novartis tracking strokes across continents https://bit.ly/46ECVZB https://lnkd.in/gdhutcn4 True diversity means understanding and serving communities with their unique cultures and customs. It's about mutual learning, adaptation, and ensuring research feels welcoming and familiar. Together, we move towards a more inclusive future, one community at a time. #CareAccess #ClinicalResearch #ClinicalTrials
To view or add a comment, sign in
-
-
Breaking the Silence: Unraveling Bias in Drug Discovery for a Healthier Tomorrow! As we enter 2024 we thought this would be a good time to highlight a problem that has existed in our industry for far too long. The lack of inclusivity in drug development is a pressing concern that demands our collective attention! Clinical research, a cornerstone of medical progress, has grappled with persistent biases, leading to unequal access and skewed results. Ethnic minorities are often sidelined in trials, creating disparities in drug efficacy and safety due to diverse genetic responses. Diverse participation in clinical trials is the key to unlocking universally effective and safe drugs. But the bias doesn't stop there. Gender-inclusive research is equally vital. Historical tendencies to predominantly study male subjects have resulted in medications showing different effects in women. It's time to prioritize gender-inclusive protocols for a more comprehensive understanding of drug responses. Addressing these disparities is not just an option; it's a necessity for equitable healthcare outcomes. Let's make a concerted effort to diversify participant pools in clinical trials, ensuring research findings are applicable across diverse populations. Researchers, the power to bring change starts from the initial phases of clinical trials. Develop inclusive protocols through decentralized trial designs, reduce exclusion criteria, and engage patients and the public. Empowering health literacy among patients is crucial, and real-world data adds depth to our understanding, favoring equal access to treatments. Together, let's break down the barriers, fostering a future where everyone benefits equally from medical advancements! #InclusiveHealthcare #MedicalEquality #DiversityInResearch #InclusiveResearch #HealthEquity #ClinicalTrialsInclusion
To view or add a comment, sign in
-
-
The underrepresentation of patient diversity in clinical trials in the US can be attributed to various challenges, including medical mistrust, limited trial availability, restricted access, eligibility criteria, enrollment practices, and lack of awareness. While sponsors play a crucial role in promoting diversity and inclusivity in clinical trials, it is also important to examine the underlying factors that contribute to the low addressability of certain populations to medical institutions with high standards, which are often targeted as centers for clinical trials. Addressing patient diversity in clinical trials requires a multi-faceted approach that involves sponsors while also addressing the underlying systemic issues that impact the accessibility of medical institutions for underrepresented populations. The FDA released data on the average participation rates in clinical trials for new molecular entities and therapeutic biologics approved in 2020. The fin dings revealed significant disparities in the representation of different racial and ethnic groups. White participants accounted for a disproportionately high percentage (75%), while other groups had much lower participation rates (11% Hispanic, 8% Black or African American, and 6% Asian). These disparities were even more pronounced when compared to the demographic composition of the US population (61.6% white, 18.7% Hispanic, 12.6% Black or African American, and 6% Asian). In an article published in the DIA Global Forum, Jewel Martin Mia Elliott, Mantej (Nimi) Chhina, and Ebony Dashiell-Aje, PhD, put forward a specific 6-point Call to Action aimed at addressing the lack of diversity in clinical trials. #regulatoryaffairs #clinicaltrials #clinicalresearch #drugdevelopment #medicalscience
US Legal Requirements and Regulatory Guidance to Increase Clinical Trial Diversity
https://globalforum.diaglobal.org
To view or add a comment, sign in
-
Learn more about our Clinical Research team and how they work is making a meaningful impact across the globe! Don't hesitate to reach out to me if you want to discuss your future here at #ThermoFisherScientific. #ClinicalResearch #LifeAtThermoFisher
Join Our Clinical Research Services Team!
jobs.thermofisher.com
To view or add a comment, sign in
-
Fully in agreement, Jayasree Iyer. Coming out of two weeks of meetings in Geneva and Chicago, I leave torn by the juxtaposition of the discussions with global health 'leaders' comfortably discussing so-called sustainable strategies, vs conversations with advocates and others who represent the voice of those diagnosed with cancer today, who are going through their journey with absolute no hope, and those who care for them who feel hopeless. A cancer diagnosis today in many parts of the world is a humanitarian crisis for that family and community. Why is it that we feel no urgency? We can alleviate unnecessary suffering and premature death today, and because we can, we must. We should hold those in positions of power accountable and implore them to join Access to Medicine Foundation The Max Foundation and others who are poised to take action. #healthequity #accesstomedicines #LMICs
With the release of the 2024 Fortune 500, we are reminded of the immense influence and responsibility of the world’s largest companies. This year, these corporations boast $18.8 trillion in revenue, representing two-thirds of the U.S. GDP and employing 31 million people. While recognising these achievements, it is crucial for these companies to extend their efforts beyond affluent markets and serve low- and middle-income countries (LMICs). Communities in LMICs can benefit from integrating diversity, equity and inclusion (DEI) into global strategies, fostering economic equality. Active involvement of LMICs in the initiatives of pharma companies can significantly address the critical healthcare needs, saving lives and closing the gap on global health inequity. For the last nearly 20 years, our work at the Access to Medicine Foundation is a testament to this commitment. Learn more about our work here: https://lnkd.in/gwqJ6RQY These industry leaders should not only measure success by profits, but also through their positive impact on all communities. #LMICs #GlobalHealth #AccesstoMedicine Erika Fry Alyson Shontell
Access To Medicine Foundation | Access to Medicine Foundation
accesstomedicinefoundation.org
To view or add a comment, sign in
-
Attention all clinical research professionals 📢 At NoyMed CRO, we extend our heartfelt gratitude to all those who have participated in our survey for our upcoming whitepaper, "Navigating the Complexity of Vendor-Sponsor Alliances: A Comprehensive Guide to Building Sustainable, Synergistic Partnerships in a Dynamic Business Environment." Your invaluable assistance has already set us on a valuable journey 🚀 For those who haven't yet joined in, there's still time to be part of this transformative endeavor! By participating in the survey, you will play a pivotal role in unveiling the true potential of clinical research partnerships. So join us in this shared mission to elevate industry standards and make a lasting impact! Your invaluable assistance has already set us on a journey towards uncovering the true potential of clinical research partnerships 🎯 Let's forge ahead together, painting a clearer picture of the mastery of clinical research partnerships. Together, we will unlock new possibilities and pave the way for progress! ✅ . . #clinicalresearch #clinicaltrials #pharmaceutical #biotech #medicaldevice #healthcare #healthcareindustry
Fill in the Survey!
docs.google.com
To view or add a comment, sign in